Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 7711

Physicists at MIT have designed a quantum “light squeezer” that reduces quantum noise in an incoming laser beam by 15 percent. It is the first system of its kind to work at room temperature, making it amenable to a compact, portable setup that may be added to high-precision experiments to improve laser measurements where quantum noise is a limiting factor.

The heart of the new squeezer is a marble-sized optical cavity, housed in a vacuum chamber and containing two mirrors, one of which is smaller than the diameter of a human hair. The larger mirror stands stationary while the other is movable, suspended by a spring-like cantilever.

The shape and makeup of this second “nanomechanical” mirror is the key to the system’s ability to work at room temperature. When a beam enters the cavity, it bounces between the two mirrors. The force imparted by the light makes the nanomechanical mirror swing back and forth in a way that allows the researchers to engineer the light exiting the cavity to have special quantum properties.

Read more | >

By tuning the direction of the external magnetic field with respect to the crystallographic axis of the silicon wafer, an improvement of spin lifetime (relaxation time) by over two orders of magnitude was reported in silicon quantum dots. This breakthrough was carried out by a team led by academician Guo Guangcan from CAS Key Laboratory of Quantum Information, USTC, in which Prof. Guo Guoping, Prof. Li Hai-Ou with their colleagues and Origin Quantum Computing Company Limited. This work was published in Physical Review Letters on June 23, 2020.

Spin qubits based on silicon quantum dots have been a core issue in the development of large scale quantum computation due to its long coherence time and the compatibility with modern semiconductor technology. Recently, the relaxation time and dephasing time of spin qubits developed in Si MOS (Metal-Oxide-Semiconductor) and Si/SiGe heterostructure have surpassed hundreds of milliseconds and hundreds of microseconds, respectively, resulting in a single-qubit control fidelity over 99.9% and a two-qubit gate fidelity over 98%. With the success in college, labs and companies from the industry are starting to be involved in this field, such as Intel, CEA-Leti, and IMEC. However, the existence of valley states (a state associated with the dip in a particular electronic band) in silicon quantum dots could reduce spin relaxation time and dephasing time seriously via spin-valley mixing and limit the control fidelity of qubits.

Read more | >

Pipeline owners Dominion and Duke Energy announced Sunday they were cancelling the fossil fuel project due to mounting delays and uncertainty. They said the many legal challenges to the project had driven up the projected costs by almost half, from $4.5 to $5 billion when it was first announced in 2014 to $8 billion according to the most recent estimate.

Environmental and community groups, who have long opposed the project on climate, conservation and racial justice grounds, welcomed the news.

“If anyone still had questions about whether or not the era of fracked gas was over, this should answer them,” Sierra Club Executive Director Michael Brune said in a statement emailed to EcoWatch. “Today is a historic victory for clean water, the climate, public health, and our communities. Duke and Dominion did not decide to cancel the Atlantic Coast Pipeline — the people and frontline organizations that led this fight for years forced them into walking away. Today’s victory reinforces that united communities are more powerful than the polluting corporations that put profits over our health and future.”

Read more | >

Having hypertension in midlife (ages 40 through 60) is associated with elevated risk of cognitive impairment and Alzheimer’s dementia later in life, even more so than having the so-called Alzheimer’s gene.

“It is clear that cerebral vascular disease”—that is, hardening of the arteries inside our brain—“and cognitive decline travel hand in hand,” something I’ve addressed before. “However, the independent association of AD [Alzheimer’s disease] with multiple AVD [atherosclerotic vascular disease] risk factors suggests that cholesterol is not the sole culprit in dementia.”

As I discuss in my video Higher Blood Pressure May Lead to Brain Shrinkage, one of the most consistent findings is that elevated levels of blood pressure in midlife, ages 40 through 60, is associated with elevated risk of cognitive impairment and Alzheimer’s dementia later in life—in fact, even more so than having the so-called Alzheimer’s gene.

Read more | >

Aging/longevity/heathspan fans!!

Higher levels of humanin, a peptide encoded in the small genome of the mitochondria, in the body is linked to longer lifespans and better health.

Aging Journal – The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan

The scientists observed that species which are already predisposed to long life, including the naked mole rat had high levels of humanin, while mice, in contrast, experience a 40% decrease in humanin over the first 18 months of their life and primates experienced a similar notable decrease between the ages of 19 and 25.

Continue reading “More Humanin Increases Chances for Healthier Living to 100” | >

An antibody cocktail designed to prevent and treat COVID-19 is now entering late-stage clinical trials, according to reports.

When naturally infected with COVID-19, the body generates Y-shaped molecules called antibodies that latch onto the virus and mark it for destruction, or hinder its ability to infect healthy cells, Live Science previously reported. These antibodies can be drawn from recovered COVID-19 patients and injected into sick patients to bolster their immune systems against the virus, a treatment known as convalescent plasma therapy.

Read more | >

Gaithersburg, Md.-based Novavax said the funding will allow the company to participate in Operation Warp Speed, the government’s program that has a goal of supporting the development of hundreds of millions of vaccine doses by 2021. The funding granted to Novavax will support the late-stage clinical development of the vaccine candidate, including a pivotal Phase III study. Additionally, the funds will be used to establish large-scale manufacturing in order to deliver 100 million doses of NVX‑CoV2373 by the end of the year.

Stanley C. Erck, president and chief executive officer of Novavax, said the company was honored to partner with Operation Warp Speed, a program that is supporting multiple shots on goal against COVID-19 by backing multiple vaccine projects, including Moderna’s mRNA program and AstraZeneca’s vaccine candidate.

“The pandemic has caused an unprecedented public health crisis, making it more important than ever that industry, government and funding entities join forces to defeat the novel coronavirus together. We are grateful to the U.S. government for its confidence in our technology platform, and are working tirelessly to develop and produce a vaccine for this global health crisis,” Erck said in a statement.

Read more | >